文献速递细菌感染、耐药与抗菌药物新发突发、热带与寄生虫病

抗铜绿假单胞菌抗生素强度与囊性纤维化儿童新发铜绿假单胞菌感染后治疗 emergent 病原体风险的相关性

Association of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired Pseudomonas Aeruginosa.
PubMed 文献 · Clin Infect Dis · 2021-01-01

本研究基于 EPIC 临床试验中 249 例囊性纤维化(CF)新发铜绿假单胞菌(Pa)感染儿童,分析抗铜绿假单胞菌抗生素暴露强度与耐药病原体获得风险的关系。随访 5 年发现,吸入抗生素暴露未增加任何病原体获得风险;每增加一周口服抗生素,木糖氧化无色杆菌获得风险增加(HR 1.24);静脉抗生素治疗与多重耐药 Pa(HR 2.47)和 MRSA(HR 1.57)获得风险增加相关。

要点

  • 吸入抗铜绿假单胞菌抗生素未增加耐药病原体获得风险。
  • 口服抗生素每增加一周,木糖氧化无色杆菌获得风险增加。
  • 静脉抗生素治疗与多重耐药 Pa 和 MRSA 获得风险增加相关。

核心结论

  • 在 CF 新发 Pa 感染儿童中,口服和静脉抗铜绿假单胞菌抗生素暴露与特定耐药病原体获得风险增加相关,而吸入抗生素未显示此风险。

研究设计与样本

  • 基于 EPIC 随机对照试验(比较 Pa 清除策略)的队列分析,纳入 249 例 CF 新发 Pa 感染儿童,随访 5 年。

主要发现

  • 吸入抗生素暴露未增加任何病原体获得风险。
  • 口服抗生素每增加一周,木糖氧化无色杆菌获得风险增加(HR 1.24;95% CI 1.02-1.50;P = .03)。
  • 静脉抗生素治疗与多重耐药 Pa 获得风险增加相关(HR 2.47;95% CI 1.28-4.78;P = .01)。
  • 静脉抗生素治疗与 MRSA 获得风险增加相关(HR 1.57;95% CI 1.03-2.40;P = .04)。

临床怎么用

  • 在 CF 儿童 Pa 清除治疗中应审慎选择抗生素,平衡清除获益与耐药病原体获得风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While Pseudomonas aeruginosa (Pa) eradication regimens have contributed to a decline in Pa prevalence in people with cystic fibrosis (CF), this antibiotic exposure might increase the risk of acquisition of drug-resistant organisms. This study evaluated the association between antipseudomonal antibiotic exposure intensity and acquisition risk of drug-resistant organisms among children with CF and new Pa infection. METHODS: We utilized data from the Early Pseudomonas Infection Control Clinical Trial (EPIC CT), a randomized controlled trial comparing Pa eradication strategies in children with CF and new Pa. The exposure was the number of weeks of oral or inhaled antipseudomonal antibiotics or ever versus never treatment with intravenous antipseudomonal antibiotics during the 18 months of EPIC CT participation. Primary outcomes were risks of acquisition of several respiratory organisms during 5 years of follow-up after EPIC CT estimated using Cox proportional hazards models separately for each specific organism. RESULTS: Among 249 participants, there was no increased acquisition risk of any organism associated with greater inhaled antibiotic exposure. With each additional week of oral antibiotics, there was an increased hazard of Achromobacter xylosoxidans acquisition (HR, 1.24; 95% CI: 1.02-1.50; P = .03). Treatment with intravenous antibiotics was associated with an increased hazard of acquisition of multidrug-resistant Pa (HR, 2.47; 95% CI: 1.28-4.78; P = .01) and MRSA (HR, 1.57; 95% CI: 1.03-2.40; P = .04). CONCLUSIONS: Results from this study illustrate the importance of making careful antibiotic choices to balance the benefits of antibiotics in people with CF while minimizing risk of acquisition of drug-resistant organisms.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Cogen JD, Onchiri FM, Hamblett NM, et al. Association of Intensity of Antipseudomonal Antibiotic Therapy With Risk of Treatment-Emergent Organisms in Children With Cystic Fibrosis and Newly Acquired Pseudomonas Aeruginosa. Clin Infect Dis. 2021. PMID: 33693586. doi:10.1093/cid/ciab208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。